

At the end of 2005, Antibiotice reports a 51% increase of gross profit

According to the financial statement approved by the General Meeting of the company's shareholders on Friday, April 28, Antibiotice reported for the last year a turnover of 45.2 million EUR (i.e. 163.5 million RON), 35% higher than that of 2004 when the turnover reached 33.6 million EUR (i.e. 136 million RON). The gross profit of the company also increased, by 51%, to 6.5 million EUR (i.e. 23.7 million RON) at the end of 2005, as compared to 4.3 million EUR (i.e. 17.6 million RON) reported at the end of 2004.

The significant increase in the turnover is primarily the result of the consolidation of the position held by the company on the market in the segments of antiinfectives, dermatologicals and topical preparations (therapeutic classes for which the producer holds market shares between 60 and 80% in terms of volume), as well as of the development of new products intended for cardiovascular and central nervous system therapy – which products account for approximately 10% of the company's turnover.